From what I can see, the market for FSGS is significantly larger than Neuren's main target - Trofinetide (Dayblue) for Retts Syndrome.
The global market for Retts is up to 9,000 patients in USA and 50,000 globally - with an anticipated market value of US$515M by 2029.
In other words, DXB's current main target, FSGS, is around 6 times larger (in patient numbers) and circa 12 times larger (in potential revenue, based on the 2032 forecasts).
https://www.maximizemarketresearch.com/market-report/rett-syndrome-market/187774/
Ann: Dimerix Receives Initial Upfront Payment from Advanz Pharma, page-120
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $203.3M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.3¢ | $404.3K | 1.094M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 84998 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 21976 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |